Skip to main content

Table 4 Univariate and multivariate analysis for recurrence-free survival (RFS) predictors in 38 patients with BCBM that were removed by gross total resection

From: Analysis of stromal PDGFR-β and α-SMA expression and their clinical relevance in brain metastases of breast cancer patients

Characteristics

No.

Mean (months)

P-value (univariate)

P-value (multivariate)

Hazard ratio

95% CI

Age (year)

< 60

25

48.5

0.780

0.275

1

0.571–7.164

≥ 60

13

31.8

2.023

Sex

Female

37

---

---

---

  

Male

1

---

  

Molecular type

Non-TN

26

52.5

0.063

0.029

1

1.158–15.256

 

TN

12

13.5

4.202

CAF pattern

Type B

15

43.2

0.424

0.254

1

0.112–1.782

 

Others

23

41.8

0.447

PDGFR-β

Low

21

31.2

0.011

0.030

1

0.060–0.868

High

17

50.1

0.228

α-SMA

Low

20

28.3

0.080

---

  

High

18

56.4

  

Tumor location

Supratentorial

29

45.3

0.968

---

  

Infratentorial

9

25.6

  

Extracranial Mets

Absent

10

28.0

0.074

0.072

1

0.106–1.099

Present

28

44.0

0.341

BM symptom

Mild to moderate

24

48.3

0.500

---

  

Severe

14

33.4

 

KPS

≥ 80

25

44.1

0.806

---

  

< 80

13

38.5

  

BM multiplicity

Single

20

32.9

0.066

---

  

Multiple

18

48.1

 

BM development

Metachronous

37

---

---

---

  

Synchronous

1

---

  

BM size

< 4 cm

19

39.0

0.428

---

  

≥ 4 cm

19

41.3

  

Peritumoral edema

Mild to moderate

16

38.9

0.676

---

  

Severe

22

43.7

  

Tumor nature

Solid

23

45.1

0.919

---

  

Cystic or mixed

15

38.6

  

Postoperative RT/GKS

Absent

9

22.8

0.249

---

  

Present

29

42.2

 
  1. BC, breast cancer; BM, brain metastasis; α-SMA, alpha-smooth muscle actin; CAF, cancer-associated fibroblast; GKS, gamma knife radiosurgery; KPS, Karnofsky performance score; Mets, metastasis; PDGFR-β, platelet-derived growth factor receptor-beta; RT, radiation treatment; TN, triple negative